Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (341-350 of 442) with videos related to

Pageof 45
Sort By:
JMIR Medical Education|December 30, 2021
Trauma Care Training in Vietnam: Narrative Scoping ReviewBa Tuan Nguyen, Toi Lam Phung, Thi Hong Hanh Khuc, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2014
Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infectionEmma E Page, Louise Greathead, Rebecca Metcalf, et al.
AIDS (London, England)|March 19, 2019
Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocationJames B Maurice, Lucy Garvey, Emmanuel A Tsochatzis, et al.
Journal of the American Heart Association|April 16, 2025
Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control TrialThanh G Phan, Velandai K Srikanth, Dominique A Cadilhac, et al.
Antiviral Therapy|February 28, 2017
Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT StudyChristoph Boesecke, Gurmit K Jagjit Singh, Stefan H-A Scholten, et al.
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2015
Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapyAlan Winston, Sophie Jose, Martin Fisher, et al.
Health Research Policy and Systems|April 22, 2021
Applying a framework to assess the impact of cardiovascular outcomes improvement researchMitchell N Sarkies, Suzanne Robinson, Tom Briffa, et al.
Family Medicine and Community Health|August 21, 2023
Absolute cardiovascular risk assessment by Australian early-career general practitioners: a cross-sectional studyToby Morgan, Anna Ralston, Andrew Davey, et al.
Journal of Medical Virology|July 15, 2003
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spotsAli Judd, John Parry, Matthew Hickman, et al.
Pageof 45

Showing results (341-350 of 442) with videos related to

Sort By:
Pageof 45
JMIR Medical Education|December 30, 2021
Trauma Care Training in Vietnam: Narrative Scoping ReviewBa Tuan Nguyen, Toi Lam Phung, Thi Hong Hanh Khuc, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2014
Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infectionEmma E Page, Louise Greathead, Rebecca Metcalf, et al.
AIDS (London, England)|March 19, 2019
Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocationJames B Maurice, Lucy Garvey, Emmanuel A Tsochatzis, et al.
Journal of the American Heart Association|April 16, 2025
Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control TrialThanh G Phan, Velandai K Srikanth, Dominique A Cadilhac, et al.
Antiviral Therapy|February 28, 2017
Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT StudyChristoph Boesecke, Gurmit K Jagjit Singh, Stefan H-A Scholten, et al.
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2015
Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapyAlan Winston, Sophie Jose, Martin Fisher, et al.
Health Research Policy and Systems|April 22, 2021
Applying a framework to assess the impact of cardiovascular outcomes improvement researchMitchell N Sarkies, Suzanne Robinson, Tom Briffa, et al.
Family Medicine and Community Health|August 21, 2023
Absolute cardiovascular risk assessment by Australian early-career general practitioners: a cross-sectional studyToby Morgan, Anna Ralston, Andrew Davey, et al.
Journal of Medical Virology|July 15, 2003
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spotsAli Judd, John Parry, Matthew Hickman, et al.
Pageof 45